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CHAPTER 1 
 
INTRODUCTION 
 
Overview of Breast Cancer 
 
Introduction 
 According to the National Cancer Institute, 207,090 new cases of breast cancer are 
discovered each year (1).  The incidence of breast cancer has increased by about 2% each 
year for the last few decades  (2).  While primary breast cancer tumors themselves are 
usually painless and have relatively few major complications, the tumors can metastasize 
and travel throughout the body, causing malignant tumors in essential organs which can 
result in death.  The National Cancer Society estimates an average of 39,840 deaths from 
breast cancer annually (1).  The probability of death from breast cancer varies widely across 
patients with differing tumor size, estrogen receptor status, and age of diagnosis (3).  Breast 
cancer treatment and prognosis are greatly correlated with tumor expression of certain 
receptors, such as the estrogen receptor (ER) and the human epidermal growth factor 
receptor 2 (HER2).   
 
Risk Factors 
 Breast cancer can occur in both genders; however, it is more prevalent in women 
than men (2).   Genetic, hormonal, and dietary factors are thought to contribute to the 
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likelihood of the development of breast cancer (4).  Numerous studies have investigated the 
effect of environmental factors versus genetic factors and the indications for development of 
breast cancer.   
Breast cancer can be caused by genetic mutations.  The high incidence of breast 
cancer among first degree relatives: grandmother, mother, aunt, daughter, or sister, suggests 
a strong genetic factor; however, families are likely to also live in similar environments and 
lifestyles (2).   Five to ten percent of all women with breast cancer have a mutation of the 
BRCA-1 and BRCA-2 genes (5).  Individuals with either but not both mutations do not have 
an increased incidence of  breast cancer (5).  The estimated lifetime risk of developing 
breast cancer for women with both mutations is estimated between 40-85% (5). 
 In addition to genetic predisposition, many environmental factors are correlated with 
an increased or decreased risk of breast cancer.  Breast cancer has a much higher incidence 
in developed countries (2).  Additionally, breast cancer occurs more frequently among 
women of professional or managerial professions as compared with manual labor workers 
(2).  Obesity has also been linked to an increased risk of postmenopausal onset of breast 
cancer (2).   
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Figure 1.1: Breast cancer incidence and mortality.  Incidence (1a) and mortality (1b) of 
American women with breast cancer across five ethnic groups: whites, Hispanics, African 
Americans, Asians/Pacific Islanders, and American Indians/Alaskan Natives (1).
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 Breast cancer incidence and mortality rates are linked with ethnicity (Fig. 1.1).  
According to reports from the National Cancer Institute, white American women have the 
highest incidence of breast cancer (6).  However, African-American women have the 
highest mortality rates from breast cancer (6).  Incidence and mortality of breast cancer is 
lowest in Hispanics, Asians/Pacific Islanders, and American Indians/Alaskan Natives. 
 Several risk factors have been correlated with higher risk for breast cancer 
development.  Incidences of breast cancer increase with age (2).  A prior history of benign 
breast disease is correlated with later onset of breast cancer (2).  Also, radiation, from atomic 
bombs or medicinal purposes, such as tuberculosis treatments, is a direct cause of breast 
cancer (7).  Many other factors have been investigated as indicators contributing to the 
development of breast cancer; however, often studies are inconclusive whether 
environmental factors are causal or incidental.   
 
Diagnosis 
 The diagnostic process for breast cancer has evolved to include many procedures 
and imaging modalities.  The initial suspicious lump is generally discovered by the patient 
or doctor during a physical examination (2).  Symptoms of breast cancer include presence of 
a lump or thickening of the breast, change in the size or shape of the breast, changes in the 
skin of the breast, and fluid discharge (7).  Usually the lump is painless, but on retrospect, 
the patient may remember mild discomfort from the area (2).  Due to increased rates of 
survival and treatment outcomes with early cancer detection, women aged 50 to 74 are 
encouraged to have biennial screenings for breast cancer . 
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 Several imaging modalities are used to detect lumps in the breast that are too small 
to be found in a physical exam.  A mammogram is an x-ray image of the breast tissue which 
can show lumps and calcified tissues (7).  Ultrasound can be used to image calcified 
tumors.(7).  MRI images are also used to distinguish normal breast tissue from benign 
lesions (7).    
Fine needle aspiration and core needle biopsy procedures extract cells of suspicious 
lumps for histological analysis.  In fine-needle aspiration, a needle is used to extract a small 
amount of liquid from the cyst or lump to determine the pathology of the suspicious lesion 
(2).  Fine-needle aspiration is performed on large tumors and fluid filled tumors.  A core 
needle biopsy is used to extract cells of lesions that are less than 2 cm for histological 
analysis (2).  Open surgical biopsy can also be performed if the lump is too small for the 
needle biopsies or if the needle biopsies are inconclusive (2).  
 Histopathology of the biopsied tissue provides characterization of the tumor and 
guides therapy selection.  Pathologists inspect the cells for the presence of abnormal or 
cancerous cells.  The biopsied cells are also stained for expression of ER and HER2 to 
determine if the patient is eligible for targeted therapies.   
 
Normal Breast Anatomy 
 The normal breast consists of several structures including the fatty connective tissue, 
secretory lobes, and ducts.  Breasts contain 15-25 lobes which are the tubulo-acinar glands 
(8).  The lobes are arranged radially at different depths around the mammary papilla (8).  
Each lobe can be divided into lobules.  A lobule is a system of ducts, the alveolar ducts (8).  
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Lobules are separated by loose connective tissue and lobes are separated by dense 
connective tissue and adipose tissue (8).   
 
Common Breast Cancers 
 A carcinoma is a malignant tumor derived from epithelial cells (2).  In breast tissue, 
epithelial cells line the ducts, acini, or lobules which are the locations where breast cancer 
can develop (2).  When examined microscopically, cancer cells exhibit changes within the 
cell different from normal epithelial cells (2).   When viewed macroscopically, the changes 
within the cells cause alterations in the arrangement of cells in relation to each other leading 
to the tumor appearance (2).  Breast cancer can be divided into two main categories: in situ 
carcinoma and invasive carcinoma.  In situ carcinoma is where the proliferating, malignant 
cells are confined by the basement membrane surrounding the ducts.  Invasive carcinomas 
are cases where the proliferating cells invade the breast stroma and tissue spaces (2).   
 
In Situ Carcinoma 
 In situ carcinoma is commonly expressed in association with invasive carcinoma; 
however, in situ carcinoma can present independently of invasive carcinoma in cases where 
the cancer cells are contained within the basal membrane of the duct (Fig. 1.2) (2).  Between 
1 and 5 % of breast cancer cases are independent in situ carcinoma, but this number is 
expected to increase as women are screened at increasingly younger ages (4).  In situ 
carcinoma includes four classifications of breast cancer, ductal carcinoma, 59% of in situ 
carcinomas, lobular carcinoma, 28% of in situ carcinomas, Paget's disease, and intracystic 
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carcinoma (2).  Often, mixed ductal and lobular carcinomas are observed in the same breast 
(1).   
 
Figure 1.2: Carcinoma in situ. In ductal carcinoma in situ, diseased tumor cells are 
confined by the duct (7). 
 
 
Histologically, ductal carcinoma tissue can appear normal or nodular with the 
involved ducts dilated, indurated, or containing a gray secretion (2).   Ductal carcinoma can 
be found in any duct of the breast and often multiple ducts present with cancerous cells (7).  
The involved ducts are noticeably enlarged and may appear distorted but preserve a well-
defined contour.  As an in situ carcinoma, ductal carcinomas are surrounded by the 
basement membrane and confined to the ducts.   
 
Figure 1.3: Invasive carcinoma.  Invasive carcinoma cells outgrow the duct and spread 
into the surrounding tissue (7).
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Invasive Carcinoma 
 When the cancer cells spread outside of the duct, the cancer is called invasive 
carcinoma (Fig. 1.3).  The most common form of breast cancer is invasive ductal carcinoma 
which affects about 77% of all breast cancer cases (2).  While these tumors have large 
variation in shape, size, and physiology; generally, invasive ductal carcinoma tumors 
include glandular structures and are separated by a fibrous membrane (4).  Additional forms 
of invasive breast cancer include invasive lobular carcinoma, medullary carcinoma, 
mucinous carcinoma, among others; however, invasive carcinomas are more generally 
classified by stage to determine best treatment. 
 
Role of Receptors 
 
Estrogen Receptor (ER) 
 The estrogen receptor is not typically expressed in normal breast cells.  The estrogen 
receptor is a transcription factor, meaning that upon activation by estrogen, the transcription 
of certain genes is increased (9).  Estrogen receptors are found on the cells of many different 
organs including the endometrium and hypothalamus (10). 
 The estrogen receptor has several functions in breast cancer tumors.  The estrogen 
receptor can act as a transcription factor.  In this pathway, estrogen binds to the estrogen 
receptor causing it to phosphorylate, which dissociates several attached proteins such as heat 
shock protein 90 (HSP-90), resulting in an estrogen receptor with a different conformation 
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in an active form (11).  The activated estrogen receptor binds with other factors, co-
activators or co-repressors, in the nucleus to moderate gene transcription (11).  Estrogen 
receptors can also activate non-genomic pathways in the cytoplasm.  In one example, the 
activated estrogen receptor activates the mitogen-activated protein kinase pathway (MAPK) 
which increases cellular metabolism and promotes cell growth (11).  Hormonal therapies, 
such as tamoxifen, bind ER without activating it, reducing the oncogenic effects of ER 
signaling. 
 
Human Epidermal Growth Factor Receptor 2 (HER2) 
  
Figure 1.4: HER2 and PI3K pathway. HER2 pathway activation increases metabolism 
and glucose uptake through activation of PI3K and AKT (12). 
 
HER2 is overexpressed in approximately 30% of primary breast cancer tumors and 
is associated with more aggressive tumors, increased recurrence, and poor patient outcomes 
(13).  HER2 is commonly expressed in breast tissue, including non-cancerous cells; thus, 
overexpression beyond the basal expression of normal tissue is clinically monitored.  Breast 
tumors are tested for HER2 overexpression by fluorescence in situ hybridization which 
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labels copies of the HER2 gene with fluorescence tags (14).  The HER2 pathway is thought 
to activate PI3K, a major driver of cellular metabolism (Fig. 1.4).  HER2 inhibitors prolong 
survival in responsive patients by impairing the oncogenic effects of HER2 signaling (15). 
 
Current Treatments 
Introduction 
Core needle biopsy, fine-needle aspiration cytology, and histological confirmation 
are used to determine the malignancy of the tumor.  A biopsy provides receptor status which 
guides treatment decisions (16).  Mastectomy is a complete surgical removal of the infected 
breast.  Common surgical management includes breast-conserving surgery paired with 
radiation therapy, mastectomy and reconstruction, and mastectomy without reconstruction.  
During surgery, lymph nodes are removed and dissected to determine whether metastases 
from the breast cancer tumors have migrated to the lymph nodes and throughout the body.   
 Treatments for breast cancer include surgical intervention, chemotherapy, radiation, 
and targeted therapeutics.  Often, breast cancer treatment involves a multimodal approach, 
using several different therapies to combat different aspects of the disease.  Age, 
menopausal state, disease stage, histology, and receptor expression influence the selection of 
therapy to optimize treatment to each specific cancer.   
 Doctors utilize a variety of treatments for ductal in situ carcinoma.  Until recently, 
mastectomy was the most common surgical intervention and treatment of ductal in situ 
carcinoma (17).  Mastectomy was preferred because other surgical interventions, such as 
partial removals, removing only the suspicious lesion, had a high recurrence, 25-50% while 
only 1-2% of mastectomy patients had recurrence; however lumpectomy, removal of the 
suspicious lesion plus a safety margin, procedures have greatly improved (17).  Current 
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treatments for ductal in situ carcinoma involve a combination approach, attacking the cancer 
in several manners.  The combined approach of tamoxifen therapy and surgery reduces same 
breast recurrence at 5 years and reduces contralateral occurrence (18, 19).  The combined 
drug and surgery regimen seeks to remove the primary tumor and selectively kill remaining 
cancer cells. 
 Likewise, lobular in situ carcinoma is treated with a variety of treatment options.  
Lobular in situ carcinoma is not malignant but an indication that a women is at increased 
risk for the development of invasive cancer (1).  Tamoxifen is a common treatment for 
reducing the risk of developing breast cancer in women with lobular in situ carcinoma (20). 
 The treatment of late-stage or inflammatory breast cancer is a similar multimodal 
approach.  A biopsy first provides histology of the breast cancer revealing ER status, 
progesterone receptor status, and HER2 status.  Radiation, hormonal, and chemotherapy 
treatments are attempted initially (1).  Upon favorable prognosis with the initial therapy, 
surgery will be performed (1).  Stage IV, recurrent, and metastatic breast cancer is combated 
with a variety of surgical, radiation, and hormonal therapies.  Traditionally, tamoxifen is 
used as a hormonal treatment for ER positive tumors.   
 
Targeted Breast Cancer Therapies 
Recent breast cancer research has focused on therapeutic agents targeting specific 
pathways within the cancerous cell.  Breast cancers expressing the estrogen receptor (ER) 
are often treated with tamoxifen, an ER antagonist.  Breast tumors which overexpress the 
human epidermal growth factor receptor 2 gene (HER2), which accounts for 
approximately 30% of all breast cancer patients, display more aggressive cancer 
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progression (13). Trastuzumab and lapatinib, two therapeutic agents that inhibit HER2, 
prolong survival in patients with HER2-overexpressing breast cancers (15, 21, 22).   
Recent studies have proven that tamoxifen is an effective hormonal drug for the 
systemic treatment of breast cancer (22).  An analysis of 80,273 women in 71 trials of 
tamoxifen found that after five years, the death rate by breast cancer was reduced by 31% 
(22).  In this analysis, worse outcomes were associated with ER-negative receptor status and 
a longer duration of treatment (22).  Current recommendations are that tamoxifen treatment 
be terminated after five years due to the development of tamoxifen resistant tumors (23, 24).   
Tamoxifen can be an advantageous anti-cancer agent for breast cancer cases of ER-positive 
tumors.  Currently several estrogen receptor inhibitors are in clinical trials as possible 
alternatives to tamoxifen (1).   
Breast cancers that overexpress HER2 are treated with HER2 inhibitors such as 
lapatinib and trastuzumab.  A high concentration of HER2 receptors expressed by breast 
cancer cells is associated with increased tumor progression and metastases (14).   
Trastuzumab is a monoclonal antibody that inhibits HER2 receptors.  Additionally, the 
antibodies decrease the expression of HER2 in malignant cells which reduces tumor 
progression and metastases (14).  Lapatinib is a small molecule inhibitor which binds HER2 
and prevents the formation of activated HER2 dimers, preventing the activation of the 
HER2 cascade and reducing the oncogenic effects of HER2 signaling (21).   
Drug Receptor Target Type 
Tamoxifen ER Hormone 
Lapatinib HER2 Small molecule inhibitor 
Trastuzumab (Herceptin) HER2 Antibody 
 
Table 1.1: Commonly used targeted therapies for breast cancer patients. 
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Due to the importance of choosing the correct treatment for breast cancer patients, 
tumors are screened for hormone receptors.  Currently, malignancy, ER, and HER2 
expression is determined by histology staining and fluorescence in situ hybridization 
(FISH).  Both of these methods are time-consuming, relatively subjective, and costly due 
to the need for tissue slicing, processing and staining before expert evaluation.  
Development of a technology that could be used in the clinic to quickly and accurately 
quantify malignancy and receptor expression will enable earlier initiation of treatment, 
guide selection of effective treatment, and reduce health care costs.  
 
Resistance 
Another factor influencing treatment decisions and ultimately limiting the clinical 
outcome of breast cancers is resistance to targeted therapies.  Only 57% of patients with 
ER-positive breast cancers respond to tamoxifen therapy (25).  Similarly, approximately 
one-third of breast tumors that overexpress HER2 do not respond to trastuzumab and 
lapatinib therapy (26). However, novel therapeutics are in development to overcome 
clinical resistance to these therapeutic inhibitors (15).  Early identification of the tumors 
that will respond to targeted therapies versus those that are resistant, will expedite clinical 
decisions regarding course of treatment, and will improve the clinical outcomes of breast 
cancer patients. Methods currently under development to determine tumor response to 
therapy include positron emission tomography (PET), CT and magnetic resonance 
imaging (MRI) (27-29). Evidence that tumor response to targeted inhibitors can be 
visualized was demonstrated with the use of fluoro-deoxyglocose (FDG)-PET, which is 
capable of detecting focused areas of high glucose uptake, such as is seen in many solid 
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tumors (30). A preliminary study of lapatinib-treated breast cancers showed changes in 
cellular metabolism, as measured by FDG-PET, after 1 month of lapatinib treatment (31).   
Yet, these currently available technologies provide only low resolution images, often 
require the use of radioactive contrast agents, and do not offer any information regarding 
HER2 or ER expression. Given the high cost of these procedures, it is unlikely that these 
will be adopted as standard of care, underscoring the need for more efficient, accurate, 
and cost-effective methods of identifying receptor expression and therapeutic response.   
 
 
Cellular Metabolism of Breast Cancer 
 Cellular metabolism is a potentially powerful biomarker for tissue biopsy 
analysis. Unlike normal cells that rely on oxidative phosphorylation to generate ATP, or 
that use glycolysis under anaerobic conditions, cancer cells often generate ATP through 
aerobic glycolysis (32).  This observation is generally described as the Warburg effect.  
Interestingly, ER and HER2 signaling in breast cancer cells drives aerobic glycolysis. ER 
increases glucose transport and glycolysis (33, 34).  Similarly, HER2 activated pathways 
may increase glucose transport into the cell and increase glycolysis (35, 36).  
Furthermore, resistance to therapeutic agents, including the HER2 inhibitors lapatinib and 
trastuzumab, activates hypoxia signaling in the presence of adequate oxygen, consistent 
with the activation of aerobic glycolysis. Furthermore, PI3K pathway activation, which is 
a major driver of aerobic glycolysis, is often elevated in trastuzumab- or lapatinib-
resistant breast cancer cells (37-40).   
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Motivation 
A clinical need exists for a technology capable of predicting targeted therapy response by 
breast cancer cells and monitoring therapy effectiveness.  This study tests the hypothesis 
that optical imaging of cellular metabolism can illuminate metabolic differences among 
cancerous cells and monitor therapy effectiveness and seeks to define the design 
parameters for a clinical device capable of monitoring therapy response.  Optical imaging 
of metabolism may identify those cancer cells exhibiting the Warburg effect in response 
to ER and HER2 signaling.  Metabolism imaging may identify those tumors exhibiting 
resistance to therapeutic inhibitors of these receptor pathways.  Currently, FDG-PET is 
used to determine therapy response in vivo, yet is expensive, requires the injection of 
radioactive agents, and cannot be repeated frequently.  Optical imaging has the potential 
to be developed as a tool to monitor cellular metabolism and therapy response. 
 
Fluorescence Imaging 
 Particular molecules, called fluorophores, are capable of emitting a photon of 
longer wavelength when excited by a photon of an optimal energy.  This phenomenon is 
illustrated in the Jablonski diagram (Fig. 1.5).  Several biomolecules are natural 
fluorophores, including collagen, tryptophan, NADH, FAD, and elastin.  These 
fluorophores are often referred to as 'auto-fluorescent' because the addition of fluorescent 
dyes or antibodies is not required. 
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Figure 1.5: Jablonski diagram of fluorescence.  When a fluorophore is excited by a 
photon (hυexcitation), the fluorophore enters and excited state.  Sometime later, the 
fluorophore returns to ground state and emits a photon (hυemission) (41). 
 
 
Optical Imaging of Metabolism 
Optical imaging is an ideal modality for probing chemical specificity and 
molecular contrast within tissues, including auto-fluorescence imaging of NADH and 
FAD, which allows quantitative measurements of cellular metabolism.  In oxidative 
phosphorylation, NADH is oxidized to NAD+ and FAD is reduced to FADH2 (Fig. 1.6).  
In glycolysis, NAD+ is reduced to NADH (Fig. 6).  Because fluorescence intensity is 
proportional to fluorophore concentration, the optical redox ratio (NADH fluorescence 
intensity divided by FAD fluorescence intensity) represents relative amounts of 
glycolysis and oxidative phosphorylation within a cell (42). 
 
 
 
 
 
Figure 1.6: Optical redox ratio. The optical redox ratio is the relative intensity of 
cellular NADH fluorescence to FAD fluorescence. 
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The optical redox ratio is a proven method of probing cellular metabolism and has 
been used to differentiate cancerous from non-cancerous tissues in a variety of models 
including oral  and breast cancer (42-48).  Ostrander et al. showed the optical redox ratio 
is sensitive to ER expression in breast cancer cell cultures and that treatment with 
tamoxifen decreased the redox ratio of those cells that were responsive to tamoxifen, but 
not those that were resistant (48).   The optical redox ratio is used in Chapter 2 to 
examine the changes in cellular metabolism due to HER2 expression and cellular 
response to HER2 targeted therapies. 
 
Selection of Imaging Parameters 
 Particular excitation wavelengths and emission filters were chosen to ensure 
adequate isolation of NADH and FAD fluorescence.  The peak excitation wavelength for 
NADH is near 350 nm and emission spans 400-500 nm (Fig. 1.7) (49).  FAD excitation 
peak is near 450 nm.  FAD emission spans 500-600 nm (Fig. 1.7) (49).  For this study, 
NADH was excited at 405 nm, the lowest available excitation wavelength on the 
Olympus FV-1000 microscope.  FAD was excited at 488 nm.  Emission between 410-510 
nm was collected for NADH, with the assumption that FAD excitation at 405 nm is 
negligible and FAD emission need not be filtered from the NADH emission.  For FAD, 
500-600 nm emission light was collected.   
Isolation of NADH and FAD was verified by a cyanide experiment.  Cyanide 
disrupts the electron transport chain preventing the conversion of NADH to NAD and 
FAD to FADH2.  Upon treatment with cyanide, an increase in NADH and a decrease in 
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FAD should be observed.  The results of the cyanide experiment are presented in Chapter 
2. 
 
 
Figure 1.7.  NADH and FAD fluorescence emission spectra.  Fluorescence emission 
spectra for NADH (triangle) and FAD (circle) (49).  
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CHAPTER 2 
 
OPTICAL IMAGING OF METABOLISM IN HER2 OVEREXPRESSING BREAST 
CANCER CELLS 
 
Introduction  
The course of breast cancer treatment increasingly relies on the molecular 
phenotype of the tumor.  For example, breast cancers that overexpress the estrogen 
receptor (ER) are often treated with ER-antagonists such as tamoxifen, while those that 
overexpress human epidermal growth factor receptor 2 (HER2) are often treated with 
HER2-inhibitors (e.g., trastuzumab, lapatinib).  HER2 overexpressing tumors display 
aggressive cancer progression (13) and account for approximately 30% of all breast 
cancer patients.   Treatment with trastuzumab (a monoclonal antibody which binds 
HER2) and lapatinib (a dual tyrosine kinase inhibitor that binds both HER2 and the 
epidermal growth factor receptor) has been shown to prolong survival in patients with 
HER2 overexpressing breast cancers (21, 26, 50).  Due to the importance of choosing the 
correct treatment for breast cancer patients, breast tumors are routinely screened for 
expression of ER and HER2.  Currently, ER and HER2 expression are determined by 
immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).   
Unfortunately, approximately one-third of breast tumors that overexpress HER2 do 
not respond to trastuzumab and lapatinib therapy (26).  Similarly, only 57% of patients 
with ER-positive breast cancers respond to tamoxifen therapy (25).  However, there are 
reasons to remain optimistic, as novel therapeutics are in development to overcome 
clinical resistance to these therapeutic inhibitors (15).  Early identification of those 
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cancers that respond to targeted therapies versus those that are resistant will expedite 
clinical decisions regarding the course of treatment and will improve the clinical 
outcomes of breast cancer patients.  
Methods currently under development to determine tumor response to therapy include 
positron emission tomography (PET), x-ray computed tomography (CT) and magnetic 
resonance imaging (MRI) (27-29). Evidence that tumor response to targeted inhibitors 
can be visualized was demonstrated with the use of fluoro-deoxyglucose (FDG)-PET, 
which is capable of detecting focused areas of high glucose uptake that are often seen in 
solid tumors. A preliminary clinical study of lapatinib-treated breast cancers showed 
changes in tumor metabolism after 1 month of lapatinib treatment (31).   Yet, these 
currently available technologies provide only low resolution images, are non-portable, 
and usually require the use of radioactive contrast agents. Given the high cost of these 
procedures, it is unlikely that these will be adopted as standard of care, underscoring the 
need for more efficient, accurate, and cost-effective methods of identifying receptor 
expression and therapeutic response.   
Cellular metabolism is a potentially powerful biomarker for tumor analysis. Unlike 
normal cells that rely on oxidative phosphorylation to generate ATP, or that use 
glycolysis under anaerobic conditions, cancer cells often generate ATP through aerobic 
glycolysis (32).  Interestingly, signaling through the HER2 and ER pathways in breast 
cancer cells is thought to promote aerobic glycolysis. ER increases glucose transport and 
glycolysis (33, 34).  Similarly, HER2 activated pathways may increase glucose transport 
into the cell and glycolysis (35, 36). HER2 signaling activates phosphatidyl inositol 3-
kinase (PI3K) a major driver of aerobic glycolysis (37-40).  In mouse models of HER2 
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overexpressing breast cancer, trastuzumab and lapatinib inhibited PI3K activity and 
decreased glucose uptake as measured by FDG-PET imaging (51).   Conversely, breast 
tumor cells exhibiting resistance to HER2 inhibitors display aberrantly increased PI3K 
activity and active hypoxia signaling despite the presence of adequate oxygen (39). These 
studies suggest that differences in aerobic glycolysis may reflect not only oncogene-
driven metabolic characteristics of the tumor cell, but also the effect of therapeutic 
inhibitors on tumor metabolism, and could therefore be used to distinguish tumors that 
are responsive to therapeutic inhibitors from those that are resistant.  
During oxidative phosphorylation, NADH is oxidized to NAD+ and FAD is reduced 
to FADH2.  However, the process of glycolysis causes NAD+ to be reduced to NADH.  
Therefore, the ratio of NADH to FAD is a measurement of the balance between 
glycolysis (seen in tumor cells) and oxidative phosphorylation (seen in untransformed 
cells). NADH and FAD can be measured in situ using autofluorescence optical imaging 
techniques. The optical redox ratio (NADH fluorescence intensity divided by FAD 
fluorescence intensity) is a proven method of probing cellular metabolism and has been 
used to differentiate cancerous from non-cancerous tissues in a variety of models 
including oral  and breast cancer (42-48).  Ostrander et al. showed the optical redox ratio 
is also sensitive to ER expression in breast cancer cell cultures, and that treatment with 
tamoxifen decreased the optical redox ratio of tamoxifen-sensitive cells, but not 
tamoxifen-resistant cells (48).   
The purpose of this study was to determine the effect of HER2 overexpression on the 
metabolism of breast cancer cells as measured by the optical redox ratio to determine if 
optical redox monitoring can be used as a simple, effective, low-cost biomarker for 
22 
 
monitoring HER2 status.  The hypothesis that HER2 overexpression influences cellular 
redox ratios independently of ER expression was tested.  Additionally, the impact of 
HER2 inhibition on the redox ratio in HER2 overexpressing breast cancer cells was 
measured. Finally, we determined if therapeutic resistance to HER2 inhibitors reflected 
on redox ratio measurements as a failure to reduce redox ratios in response to HER2 
inhibition.  HER2 overexpression was found to increase the redox ratio, independently of 
ER expression.   While HER2 inhibition decreased the optical redox ratios in HER2 
overexpressing cells, the HER2 inhibitor, trastuzumab, had no impact on redox ratios in 
trastuzumab resistant cells, despite continued overexpression of HER2.   
 
Materials and methods 
Cell Culture 
MCF10A cells were cultured in Mammary Epithelial Cell Growth Medium 
(MEGM, Lonza, Walkersville, MD) excluding the gentamycin-amphotericin B mix and 
supplemented with 100 ng/ml cholera toxin and 1% penicillin:streptomycin.  The BT474, 
MDA-MB-231, MCF7, and SKBr3 cells were grown in DMEM (Invitrogen, Carlsbad, 
CA), supplemented with 10% fetal bovine serum and 1% penicillin:streptomycin, 
hereafter referred to as DMEM+.  The resistant cell lines were grown in the DMEM+ at 
levels of the corresponding drug to maintain resistance.  The lapatinib resistant cells were 
grown at 1 µM lapatinib (LC Laboratories, Woburn, MA) concentration and the 
trastuzumab resistant cells were grown at 25 µg/ml.   
For imaging, all cell lines were plated at a density of 1x10
5
 cells per 35 mm plate, 
48 hours prior to imaging.  Glass bottom dishes (MatTek Corporation, Ashland, MA) 
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were used to allow live cell imaging on an inverted, confocal microscope.  The 
trastuzumab and lapatinib resistant cell redox ratio was determined from cells grown in 
trastuzumab and lapatinib supplemented media.  For the drug perturbation experiments, 
the responsive BT474 cells were fed the drug supplemented media 24 hours prior to 
imaging.  For the trastuzumab perturbation of the trastuzumab resistant cells, the cells 
were fed the DMEM+ media for the first 24 hours after plating and the DMEM+ with 
trastuzumab for the second 24 hours.  Drug concentrations of the media were selected to 
mimic therapeutic drug dosage in patients, 25 µg/ml for trastuzumab (VUMC Pharmacy, 
Nashville, TN) and 2 µM for tamoxifen (Sigma-Aldrich, St. Louis, MO) (51, 52).  
In order to verify isolation of NADH and FAD auto-fluorescence, a cyanide 
experiment was conducted. MCF10A cells were plated at 1 x 10
5
 cells per plate, 48 hours 
prior to imaging.  Cells were imaged before the addition of cyanide.  After 3 images from 
a plate were acquired, the cell media was exchanged for growth media supplemented with 
4 mM NaCN (Sigma-Aldrich, St. Louis, MO).  The cells were given one minute to react 
with the cyanide; then, 3 different places of each plate were imaged.   
Proliferation rates of MCF10A, MCF7, and BT474 cells were determined by 
antibody labeling of cells grown on parallel imaging plates.  Mitotic cells were first 
marked using a Phospho-Histone H3 (Ser10) antibody (Cell Signaling Technology, 
Danvers, MA).  Then, labeling of the primary antibody with Alexa Fluor 488 goat anti-
rabbit IgG antibody (Invitrogen, Carlsbad, CA) allowed counting by flow cytometry of 
the highly fluorescent mitotic cells and the less-fluorescent unlabeled cells.  The 
percentage of proliferating cells was determined by dividing the number of highly 
fluorescent cells into the total number of cells counted.   
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Verification of ER and HER2 Expression  
Cells were homogenized in ice-cold lysis buffer [50 mM Tris pH 7.4, 100 mM NaF, 120 
mM NaCl, 0.5% NP-40, 100 µM Na3VO4, 1X protease inhibitor cocktail (Roche)], 
sonicated for 10 s at 4ºC, 13,000 x g for 5 min. Protein concentration was determined 
using the BCA assay (Pierce). Proteins were separated by SDS-PAGE and transferred to 
nitrocellulose membranes. Membranes were blocked in 3% gelatin in TBS-T [Tris-
buffered saline, 0.1% Tween-20) for 1 h, incubated in primary antibody in 3% gelatin for 
2 h at room temperature, washed with TBS-T, incubated in HRP-conjugated anti-rabbit or 
anti-mouse IgG, washed with TBS-T, and then developed using ECL substrate (Pierce). 
The following primary antibodies were used: ErbB2 (HER2) (Neomarkers, InVitrogen; 
1:2000); ER-alpha (Santa Criz Biotechnologies; 1:1000); beta actin (Sigma-Aldrich; 
1:5000). 
 
Confocal Imaging 
Images were acquired using an Olympus FV-1000 Inverted Confocal Microscope 
with a 40X/1.3 NA oil-immersion objective.   Confocal microscopy was chosen over 
widefield fluorescence to reduce background noise for ease of NADH and FAD auto-
fluorescence measurement.  Additionally, the redox ratio is sensitive to measurement 
volumes and confocal microscopy ensures that the NADH and FAD signals can be co-
registered to the same volume.  For NADH fluorescence, the cells were excited at 405 nm 
and 410-510 nm emission was collected.  FAD was excited at 488 nm and 500-600 nm 
emission was collected.  The two images were acquired simultaneously, with NADH and 
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FAD acquired sequentially for each pixel.  A pixel dwell time of 2 µs was used.    Each 
line was averaged 4 times to reduce noise.  A single 1024x1024 pixel image required 
39.0 s to acquire.  To ensure the cells were not photobleaching, two images of the same 
field of view were acquired consecutively with no significant change in average pixel 
intensity.  Settings for the gain, offset, and pinhole were maintained constant across all 
imaging sessions.  To account for daily variations in laser power or instrumentation 
instability, the images were normalized to MCF10A cell measurements acquired during 
each imaging session.  Each plate was imaged at 3 different, non-overlapping locations.   
 
Image Analysis 
The optical redox ratio, NADH fluorescence intensity divided by FAD 
fluorescence intensity, was computed for each cell in the image using ImageJ software 
(NIH).  The fluorescence signal of non-cellular regions, or background signal, was 
removed to ensure the fluorescence comparisons were made only for the cells.  NADH 
and FAD used for cellular metabolism are contained within the cytoplasm and 
mitochondria, and the fluorescence signal from the nucleus is not involved in cellular 
metabolism.  Therefore, the fluorescence signal from the nucleus was also removed to 
ensure isolation of metabolic NADH and FAD and eliminate the possibility of nuclear 
size as a confounding factor.     Next, a NADH/FAD per pixel image was computed and 
the redox ratio for each cell in the image was determined.  The average redox ratio value 
from all cells in each image was computed and normalized to the corresponding session's 
MCF10A measurement.  Standard error was computed from the mean redox ratio value 
across all images from each cell line.  A rank sum test was used for all statistical 
comparisons.   
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Results 
The optical redox ratio of a panel of human breast-derived cell lines with varying 
expression of ER and HER2 were studied (Table 2.1, Fig. 1.1).  MCF10A, a non-
cancerous breast cell line with negligible or low expression of ER and HER2 was used as 
a control for each analysis.  Western blot analysis verified the expression of ER and 
HER2 (Fig. 1.1). 
 
 
Cell line Cancerous ER status HER2 
overexpression 
n 
MCF-10A Non-
cancerous 
- / low - / low 30 
MDA-MB-231 Cancer Negative Negative 15 
MCF-7 Cancer Positive Negative 15 
BT-474 Cancer Positive Positive 15 
SKBr3 Cancer Negative Positive 15 
HR6 (Trastuzumab  
Resistant BT-474) 
Cancer Positive Positive 15 
BT-LR (Lapatinib 
Resistant BT-474) 
Cancer Positive Positive 15 
 
Table 2.1:  Breast cancer cell lines with corresponding ER and HER2 expression. 
 
Figure 2.1: Expression of ER and HER2. Western blot analysis demonstrates 
overexpression of HER2 in the SKBR3 and BT474 cells and expression of ER in 
the MCF7 and BT474 cells. 
 
 
HER2 
Actin 
ER 
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Verification of Optical Redox Ratio Measurement 
To verify the use of optical imaging to measure the redox ratio, cyanide was used 
to disrupt the electron transport chain, thus preventing the conversion of NADH to 
NAD+ (53).  As predicted, MCF10A cells treated with cyanide exhibited increased 
NADH fluorescence (p < 0.01, Fig. 2.2) and decreased FAD fluorescence (p < 0.05; Fig. 
2.2). Therefore, the redox ratio was increased in cyanide-treated MCF10A cells as 
compared to untreated cells (p < 0.005, Fig. 2.2).  These results confirm that our optical 
imaging methods accurately reflect the balance between glycolysis and oxidative 
phosphorylation, and can be used to assess the metabolic state of tumor cells.  
 
 
Figure 2.2. Cyanide perturbation.  Addition of CN to MCF10A cells (n 
= 6) results in an increase in redox ratio and NADH fluorescence and a 
decrease in FAD fluorescence.  Bar height represents mean and error bars 
represent SE. 
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Redox Ratio of HER2 Overexpressing Cells 
Figure 2.3. Fluorescence and redox images. Representative NADH, FAD, and redox 
ratio images for MCF10A, MDA-231, MCF7, BT474 and SKBr3 cells.  Optical redox 
ratio increases with ER and HER2 expression. 
 
 
Figure 2.4. Redox ratio of malignant cells.  Quantitative representation (mean +/- SE) 
of the redox ratio values for the MCF10A (n=30), MDA-MB-231 (n=15), MCF7 (n=15), 
BT474 (n=15), and SKBr3 cells (n=15).  Redox ratio is elevated in cells overexpressing 
HER2. 
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We used optical imaging to capture NADH and FAD fluorescence in five breast 
derived cell lines (Fig. 2.3): MCF10A (untransformed breast epithelial cells), MDA-MB-
231 (ER-/HER2-), MCF-7 (ER+/HER2-), SKBR3 (ER-/HER2+), and BT474 
(ER+/HER2+). The fluorescence intensities were used to calculate the redox ratio per cell 
for each cell line (Fig. 2.4).  While ER-/HER2- MDA-MB-231 cells displayed a redox 
ratio that was similar to what was seen in untransformed MCF10A cells, redox ratios 
were elevated in all other breast cancer cell lines (p < 0.005).  ER+/HER2- breast cancer 
cell lines displayed elevated redox ratios (p<0.005), but not to the extent seen in HER2+ 
breast cancer cell lines (p<0.001).   
Figure  2.5.  Redox ratio normalized to proliferation rate. Redox ratio divided by 
proliferation rate mean +/- SE for MCF10A (n=30), MCF7 (n = 15) and BT474 (n = 15) 
cells.   
 
Controlling for differences in rates of proliferation among the MCF10A, MCF7, 
and BT474 cells did not reduce the significance of the redox ratio results shown in Fig. 
2.4.  In fact, controlling for proliferation (redox ratio divided by proliferation rate for 
each cell line) increases the differences between these three cell lines (Fig. 2.5).   
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Effect of HER2 Targeted Therapies 
Figure 2.6. Effect of HER2 inhibitors on resistant and responsive cells. (A) The redox 
ratio (mean +/-SE) of responsive BT474 cells is different from the trastuzumab  (HR6) 
and lapatinib (BT-LR) resistant cells (n=15), and there was no change in the redox ratio 
of trastuzumab-resistant HR6 cells with trastuzumab-treatment.  (B) The redox ratio of 
responsive BT474 cells decreased with tamoxifen (2 µM), trastuzumab (25 µg/ml), and 
tamoxifen + trastuzumab treatment (n=15). 
 
The redox ratio of both the trastuzumab resistant cell line, HR6, and the lapatinib 
resistant cell line, BT-LR, was lower than the redox ratio for the responsive parental 
BT474 cells (Fig. 2.6A). The HR6 cells are BT474-derived cells that continue to grow in 
the presence of trastuzumab (54).  Likewise, the BT-LR cells are BT474-derived cells 
that were selected in culture with increasing concentrations of lapatinib (55). To 
investigate the contributions of the ER and HER2 signaling pathways to the redox ratio, 
BT474 cells (ER+/HER2+) were exposed to the ER antagonist tamoxifen and the anti-
HER2 monoclonal antibody trastuzumab, (Fig. 2.6B).  Trastuzumab significantly 
decreased the redox ratio in ER+/HER2+ breast cancer cells (p<0.001; Fig. 2.6B). 
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Similarly, tamoxifen resulted in a decrease in redox ratio in the same cells (p<0.001, Fig. 
2.6B).  The combination of tamoxifen with trastuzumab decreased the redox ratio in  
BT474 cells (ER+/HER2+) to a greater extent than single agent tamoxifen (p<0.001) or 
trastuzumab (p<0.001; Fig. 2.6B).  Interestingly, treatment of HR6 cells with trastuzumab 
did not cause any alterations in the redox ratio (Fig. 2.6A).  It is difficult to fully 
eliminate the influence of lapatinib on the BT-LR cells; and therefore, outside the scope 
of this study to robustly perform a comparison of pre- and post- lapatinib treatment in 
these cells.   
 
Discussion 
The selective use of aerobic glycolysis over oxidative phosphorylation by cancer 
cells has been known for over a century. We and others have shown that this 
characteristic of cancer cells can be monitored in situ using optical imaging to measure 
the redox ratio, or the ratio of glycolysis to oxidative metabolism. Furthermore, we show 
that “driver” oncogenes in breast cancer cells also drive aerobic glycolysis in these cells. 
Specifically, HER2 activity was required for maximal aerobic glycolysis in breast cells 
overexpressing HER2, while ER signaling was required for aerobic glycolysis in ER+ 
breast cancer cells. These results demonstrate the effect of the HER2 and ER signaling 
pathways on cancer cell metabolism, as measured by the optical redox ratio.  These data 
support the conclusion that optical imaging of redox ratios can be used to measure the 
tumor cell response to therapeutic inhibitors in situ. Finally, using HER2 overexpressing 
breast cancer cells with acquired resistance to HER2 inhibitors, we demonstrated that loss 
of oncogene dependence was reflected in the optical redox ratio measurement, such that 
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HER2 inhibitors failed to decrease the redox ratio in a resistant cell line. Therefore, these 
findings could be applied to future studies using optical imaging of breast cells and 
tumors to predict their response to HER2 inhibitors, a development that would 
significantly inform clinical decisions regarding therapeutic strategies used to treat 
patients with HER2-positive breast cancers. 
While this is the first study to correlate HER2 overexpression and activity to the 
redox ratio, a previous study similarly determined that ER+ breast cells exhibited a higher 
optical redox ratio than ER-negative cells (48).  The previous study differs from the 
results presented herein because the previous study suggested that MCF7 cells 
(ER+/HER2-) exhibited a similar redox ratio to BT474 cells (ER+/HER2+). However, 
our results suggest that BT474 cells have significantly higher redox ratios than MCF7 
cells. Several experimental factors could explain the differing results, including different 
excitation wavelengths for NADH, differing emission filters, and different growth media.  
Ostrander et al. used media supplemented with 5% FBS versus 10% used in our studies, 
which may have increased cellular proliferation in our experiments versus those 
described earlier, thus affecting tumor cell metabolism (56).   However, when controlling 
for cell proliferation, the difference in the redox ratio between MCF7 and BT474 cells 
increased in the current study (Fig. 2.5).  Different emission filters capture different areas 
of the NADH and FAD emission curves, affecting absolute fluorescence intensity which 
may change the redox ratio.  The results of the cyanide experiment ensure measurement 
of NADH and FAD fluorescence for this study (Fig 9). 
The results show that redox ratios in triple-negative MDA-MB-231 cells were 
similar to what was seen in MCF10A cells, which was less than the redox ratio seen in 
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HER2+ or ER+ breast cancer cells.   Triple-negative breast cancers (TNBC) lack HER2, 
ER, and PR, so they are difficult to target and no molecular targeted therapies exist for 
these breast cancers.   Several FDG-PET studies in TNBC, ER+, and HER2+ tumors 
report high variability in the glucose uptake of triple negative cells (57, 58).  Note that 
FDG-PET imaging illuminates different aspects of cellular metabolism (glucose uptake) 
than the optical redox ratio (relative concentrations of NADH and FAD, end products of 
metabolism).  However, these previous reports indicate that the metabolism of TNBC is 
complex and heterogeneous, so a full characterization of this tumor subtype will likely 
require a more concentrated study.      
The highest redox ratios were measured in breast cancer cell lines with HER2 
overexpression.  The higher redox ratio of HER2 overexpressing cells suggests that the 
HER2 pathway may affect cellular metabolism.  Indeed, studies have found increased 
concentrations of glucose transporters and glycolytic enzymes present in HER2 
overexpressing cells versus cells with low expression of HER2 (35, 36). 
We found that HER2 inhibition with trastuzumab decreased the redox ratio of 
HER2 overexpressing breast cancer cells (p< 0.001, Fig. 2.6B).  This is consistent with 
several studies reporting reduced glucose uptake, decreased lactate secretion, and 
decreased glycolysis, in responsive HER2 overexpressing breast cancer cells treated with 
trastuzumab (59, 60).  Treatment with both trastuzumab and tamoxifen decreased the 
redox ratio of responsive BT474 cells to levels seen in the non-cancerous MCF10A cell 
line (Fig. 2.6B).  These results suggest that both ER and HER2 signaling affects tumor 
cell metabolism in breast cancer cells.  Mechanistic studies of receptor expression 
support this result.  Cells expressing ER overexpress glucose transporters and have higher 
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reported rates of glycolysis (33, 34).  Similarly, HER2 overexpression is linked with 
increased glucose transport into cells and increased glycolysis (35, 36). 
Innate and acquired resistance to HER2 inhibitors limits their current clinical 
success. Nearly all HER2-amplified breast cancers treated with trastuzumab or lapatinib 
will ultimately develop resistance to these targeted inhibitors. We examined trastuzumab-
resistant cells, demonstrating that trastuzumab failed to reduce the redox ratio in the 
resistant cells (Fig. 2.6A). These results are the first of its kind, but are consistent with an 
FDG-PET study of trastuzumab responsive and non-responsive breast cancer xenographs, 
demonstrating that HER2 inhibitors failed to reduce FDG uptake in those tumors whose 
growth was unaffected by trastuzumab (61).  Interestingly, the redox ratio of the 
trastuzumab and lapatinib resistant cells are different from the pre-treatment redox ratio 
value of responsive BT474 cells, p<0.001 (Fig. 2.6A).  These results open up the 
possibility of screening HER2-inhibitor resistance with the optical redox ratio. 
Future in vivo studies are needed to verify the influence of ER and HER2 
expression on cellular metabolism.  Increasing research is elucidating the importance of 
metabolism in cancer cells and its relationship with drug resistance.  Here, upon 
treatment with receptor targeted therapies, the change in metabolism of resistant cells is 
shown to be negligible, while the metabolism of responsive cells is significant.  
Additionally, basal redox ratios are different in resistant versus responsive cells.  
Therefore, cellular redox ratios may prove an invaluable tool for research and clinical 
identification of receptor expression, tumor resistance to targeted therapies, and for 
monitoring treatment efficacy. 
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CHAPTER 3 
 
CONCLUSION AND FUTURE DIRECTIONS 
 
 Increased optical redox ratios were found in breast cancer cells overexpressing 
HER2.  Upon treatment of responsive cells with HER2 targeted therapies, the redox ratio 
was reduced, supporting research that has correlated HER2 overexpression with 
increased glycolysis.  Cells overexpressing HER2 but resistant to HER2 targeted 
therapies expressed reduced optical redox ratios compared to HER2-therapy responsive 
cells.  These results suggest that the optical redox ratio may be further developed as a tool 
for predicting response to therapy and monitoring therapy effect on cellular metabolism. 
 
Pre-clinical System Design 
 The optical redox ratio results presented in Chapter 2 indicate that a pre-clinical 
device may be developed to monitor therapy response in pre-clinical drug studies.  
Currently, to monitor drug efficacy in pre-clinical models such as mice xenograft tumors, 
the mice are sacked at certain hours post-treatment for histological and 
immunohistochemical analysis of the tumor response.  Optical redox imaging may be 
used non-invasively through the mouse skin or an implanted window chamber to image 
the tumor's metabolic response non-invasively.  Currently PET is utilized in such a 
manner; however, PET shows no different between responders and non-responders until 
seven days post-treatment (30).  Additionally, PET measurements require lengthy 
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recovery times due to the high radiation exposure and the time for the dye to wash 
through the mouse.  Optical techniques are not limited by radiation or dyes and thus can 
be used at any time of interest. 
 A pre-clinical system design would require a fluorescence microscope capable of 
isolating NADH and FAD fluorescence emission.  NADH can be excited around 350 nm 
and FAD around 480 nm.  Emission filters can isolate NADH emission, 400-500 nm, and 
FAD emission 500-600 nm.  For pre-clinical mouse studies, the device can image tumors 
through window chambers which allow utilization of a normal microscope.  As the 
results presented in Chapter 2 show, such a device would need to be sensitive to optical 
redox ratio changes of at least 30% to effectively monitor metabolism.  
 A sub-cellular resolution is required of a pre-clinical system.  Sub-cellular 
resolution allows isolation of different sub-populations of tumor cells with different 
responses to therapy.  Several current microscopic techniques, such as confocal 
microscopy and two-photon fluorescence imaging allow sub-cellular resolution and could 
be implemented in the pre-clinical system. 
 
Clinical System Design 
 In addition to development as a pre-clinical tool, the optical redox ratio has the 
potential to be developed as a simple, effective, low cost method for identifying HER2 
overexpressing tissue and monitoring therapy in patients.  Based on the results presented 
in Chapter 2, such a device may be capable of identifying HER2 overexpressing tumors, 
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predicting drug response, and with repeated measurements over time, monitoring therapy 
response.  Table 3.1 illustrates several of the design parameters for such a device. 
Feature Design Constraints Justification 
Excite NADH  ~ 350 nm Measure NADH auto-
fluorescence 
Excite FAD  ~ 480 nm Measure FAD auto-
fluorescence 
Isolate NADH from FAD 
emission 
~ 400-500 nm / ~500-
600 nm 
Need isolation of NADH and 
FAD fluorescence 
Resolution Cellular Sub-populations of cells may 
respond differently 
Depth Best possible Sampling core and inner tumor 
may have different redox states 
Sensitivity Must measure ~30% 
difference 
This is the difference observed 
in the ER+/HER2- cells 
Size Fit into core needle Clinical measurements 
 
Table 3.1  Design parameters for clinical optical metabolic monitoring system. 
 
A clinical system would need to be capable of exciting and isolating NADH and 
FAD auto-fluorescence.  Excitation for NADH can be achieved around 350 nm and 
around 480 nm for FAD.  Filters can be used to isolate the two emission signals, with 
NADH emission between 400 and 500 nm and FAD between 500 and 600 nm.  Cellular 
resolution may be required as tumors are thought to be composed of sub-populations of 
cells with different gene expression which enables some cells to develop resistance to 
therapeutic agents (15).  The device must be able to measure changes in redox ratio of at 
least 30%, as that is the difference between normal and ER+/HER2+ cells found in 
Chapter 2.  Additional filters to block excitation light and room light from reaching the 
detector will help increase device sensitivity.   
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A large device, such as incorporation of fluorescence components into a surgical 
microscope, would require invasive procedures such as surgery to expose the tumor.  
Repeated measurements over time would not be possible from a surgical microscope. A 
clinical device would be most utilized if it may fit within a core needle to obtain 
measurements before core needle biopsy procedures.  A micro-imaging system would 
allow multiple measurements during minimally invasive procedures.  This design would 
also allow measurements at the time of diagnosis, during surgery, and post-surgery to 
monitor therapy response.    
Several different fluorescence microscope designs can be used to isolate z-depth 
information from tissue including confocal microscopy, two-photon fluorescence 
microscopy, and wide-field fluorescence with structured illumination.  A wide-field 
fluorescence microscope using structured illumination for depth resolution can be 
implemented to isolate the z-direction without the need for a confocal design.  Wide-field 
microscopes are advantageous due to image acquisition speed. 
 
Future Directions 
Further studies are necessary for the development of the optical redox ratio for 
clinical use.  Measurements from breast tumors are required to verify that the redox ratio 
remains sensitive to metabolic changes within a diverse patient population.  These studies 
will further define the parameters of a clinical system.  Furthermore, other optical 
techniques, such as the fluorescence lifetime of NADH and FAD, may provide important 
metabolic information and should be investigated.  
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